Atyr Pharma
$1.27
44
-$0.03-2.31% Friday 21:00
Statistics
Day High
1.32
Day Low
1.22
52W High
2.7
52W Low
1.08
Volume
187,696
Avg. Volume
169,094
Mkt Cap
74.37M
P/E Ratio
-1.35
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.47
-0.38
-0.29
-0.2
Expected EPS
-0.24
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow LIFE. It's not an investment recommendation.
Analyst Ratings
27.5$Average Price Target
The highest estimate is $35.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%
About
Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Show more...
CEO
Sanjay Shukla
Employees
49
Country
US
ISIN
US0021202025
WKN
000A2PM86